Blockchain Registration Transaction Record

Regentis Biomaterials Targets $3B Cartilage Repair Market with GelrinC

Regentis Biomaterials (RGNT) targets $3B cartilage repair market with GelrinC, an off-the-shelf regenerative platform simplifying knee cartilage repair via a 10-minute procedure.

This matters because cartilage defects are a common and debilitating condition, affecting hundreds of thousands of patients each year and often leading to chronic pain and osteoarthritis. Current treatments are invasive, costly, and may not provide durable repair. Regentis' GelrinC offers a simpler, single-step procedure that could dramatically improve patient outcomes, reduce healthcare costs, and set a new standard of care. For investors, the company's positioning in a $3 billion market with growing demand for regenerative solutions presents a significant opportunity.